Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Robigo Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution effort is limited to 1 distinct examiner, showing a specific technical and examiner engagement. For a practitioner, this means that the outcome of the company's active patent efforts is entirely dependent on the review of this specific individual and the standards of the assigned art unit. The prosecution is currently confined to the distinct art unit, which indicates a narrow technical focus for the company's active filings.
The busiest examiner for the company is ORDAZ, CHRISTIAN JOSE, who is assigned the pending office action. Since there is only 1 pending office action in total, this examiner holds the entirety of the company's active workload. This concentration allows for a focused prosecution strategy, but it also means the company lacks the diversification that comes with having matters spread across multiple examiners. Practitioners should focus on the specific historical allowance rates and tendencies of ORDAZ, CHRISTIAN JOSE, as this individual's decisions will define the current success of the company's patent filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORDAZ, CHRISTIAN JOSE | 1 | 66.7% | +78.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264004 | PLANT MICROBES AND USES THEREOF | ORDAZ, CHRISTIAN JOSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264004 | PLANT MICROBES AND USES THEREOF | ORDAZ, CHRISTIAN JOSE | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19264004 | PLANT MICROBES AND USES THEREOF | ORDAZ, CHRISTIAN JOSE | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jul 09, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRobigo Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christian Jose Ordaz has the most, with 1 of Robigo Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
